Several other ICIs have been studied for use in cSCC, including nivolumab (anti-PD-1), ipilimumab (anti-CTLA04), avelumab (anti-PD-L1), and relatimab (LAG-3). This evidence concerns the gene CD274 and skin squamous cell carcinoma.